NF2 Clinical Trials

If you are a person with NF2, please consider participating in a research study that evaluates treatment for NF2.


  • A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas

    This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Location: Massachusetts General Hospital, Boston, MD

  • AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

    The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.

    Location: Massachusetts General Hospital, Boston, MD

  • Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

    The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients.

    Location: University of California Los Angeles, CA

  • Neurofibromatosis (NF) Registry Portal

    The NF Registry is a database of patient-reported experiences of living with neurofibromatosis. It also serves as a referral source for clinical trials.

    Location: Online,

  • Effect of Implant Position on Magnetic Resonance Image Distortion

    The aim of this study is to find the optimum head position in relation to the MRI magnet field, which would produce least area of image distortion in patients with ABIs. This will be of benefit in optimising the MR imaging in future patients with implants.

    Location: Manchester, UK

  • Sorafenib in NF2 Skin Schwannomas

    Adults who have Neurofibromatosis 2 (NF2) and skin tumour(s) (nerve tumours under the skin also referred to as ‘schwannomas’) accessible for two biopsies are invited to participate in a research study being undertaken initially in Plymouth and Manchester, with further sites becoming involved when necessary. Professor C. Oliver Hanemann, a consultant neurologist at the Peninsula College of Medicine and Dentistry in Plymouth, is the Chief Investigator.

    Location: Plymouth and Manchester, UK

  • Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

    The purpose of this study is to determine if the study drug, AXITINIB, has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2).

    Location: NYU Langone Medical Center, New York

  • Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

    The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry. This is a “phase 0” PK (pharmacokinetic) and PD (pharmacodynamic) study of RAD001 in patients with Neurofibromatosis Type 2-related and sporadic VS and meningiomas. Enrolled patients will take RAD001 prior to a scheduled VS or meningioma surgery, and blood and tissue samples will be obtained for further analysis.

    Location: NYU School of Medicine, New York

  • Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas (NF-2)

    To determine the hearing response rate at 24 weeks after treatment with bevacizumab for symptomatic vestibular schwannomas (VS) in children and young adults with NF2.

    Locations: Children’s Hospital Los Angeles, Children’s National Medical Center (District of Columbia), University of Chicago, Indiana Unversity, Children’ Hospital Boston and Massachusetts General Hospital, Washington University – St. Louis, New York University Medical Center, Cincinnati Children’s Hospital Medical Center, Children’s Hospital of Philadelphia, University of Utah

  • Auditory brainstem implant (ABI) patients needed for research study at MEEI and MGH

    A clinical research study of patients who have an auditory brainstem implant (ABI) is being conducted jointly by researchers. We will use specialized hearing testing to better understand how your brain responds to stimulation from your ABI.

STATUS: Unknown

  • Concentration and Activity of Lapatinib in Vestibular Schwannomas

    This study is exploring whether a drug that is approved by the FDA and is currently used to treat breast cancer might also work to treat VS. This study will measure the amount of drug that travels from the bloodstream and arrives at the tumor.

    Locations: House Research Institute (California), Johns Hopkins Hospital (Maryland), Massachusetts General Hospital, Washington University Medical Center, NYU Medical Center, Well Cornell Medical College (New York), Ohio State University Medical Center